Patritumab

monoclonal antibody

Identifier: CI-DRUG-00000459
Entity page: /drug/patritumab ↗
Edges: 22

Neighbours: 11 cancers1 genes1 variants6 trials
Drawn: 19 of 19 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Patritumab predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	NRG1 Expressionexpression	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
Patritumab targets …TARGETS1 of 1
→ targets

Patritumab investigated for …INVESTIGATED_FOR8 of 8
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	3	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	3	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	2	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Angiosarcomasubtype	unknown	2	Angiosarcoma	1	Curated	chembl	graph →
→ investigated for	Head and Neck Neoplasmcancer_family	unknown	2	Head and Neck Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	1	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	1	Squamous Cell Carcinoma	1	Curated	chembl	graph →

Patritumab investigated for …INVESTIGATED_FOR8 of 8

→ investigated for

Lung Non-Small Cell Carcinomasubtype

supports

Lung Non-Small Cell Carcinoma

Curated

Patritumab investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Neoplasmcancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Patritumab studied in …STUDIED_INderived6 of 6
→ studied in	NCT01211483Phase 1/Phase 2 · completed Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer · 6 trials list this drug (0 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02633800Phase 2 · terminated Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) · 6 trials list this drug (0 active)	—	—	Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02350712Phase 1 · completed Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer · 6 trials list this drug (0 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02134015Phase 3 · terminated Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) · 6 trials list this drug (0 active)	—	—	Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01512199Phase 1/Phase 2 · terminated Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) · 6 trials list this drug (0 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01957280Phase 1 · completed Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287) · 6 trials list this drug (0 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths